Omeros Corporation To Discontinue ARTEMIS-IGAN Trial, Which Did Not Reach Statistical Significance On The Primary Endpoint Of Reduction In Proteinuria From Baseline Compared To Placebo
Portfolio Pulse from Bill Haddad
Omeros Corporation has decided to discontinue the ARTEMIS-IGAN trial as it did not reach statistical significance on the primary endpoint of reduction in proteinuria compared to placebo.
October 16, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Omeros Corporation's decision to discontinue the ARTEMIS-IGAN trial could negatively impact the company's stock price in the short term.
The discontinuation of a clinical trial often leads to a decrease in the stock price of the company conducting the trial. This is because the discontinuation is seen as a failure to achieve the desired results, which can negatively impact the company's future revenue and growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100